BioNTech SE · NASDAQ:BNTX
BioNTech — Merger or Acquisition (June 2025)
8 slides from BioNTech's merger presentation, Jun 2, 2025
Slide 1: A Transformative Global Partnership for BNT327
A Transformative Global Partnership for BNT327 (PD-L1 x VEGF-A bispecific antibody) June 2, 2025 Exhibit 99.2
Slide 2: This Slide Presentation Includes Forward-Looking Statements
2 This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expectations regarding the impact of the c
Slide 3: Forward Looking Statements and Non-GAAP Financial Information
3 Forward Looking Statements and Non-GAAP Financial Information This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products
Slide 4: BioNTech and Bristol Myers Squibb Enter Landmark Strategic Partnership to Advance BNT327 & Oncology Leadership
BioNTech and Bristol Myers Squibb Enter Landmark Strategic Partnership to Advance BNT327 & Oncology Leadership 4 Potential to transform standard of care and establish new IO backbone treatment option for patients with high unmet medical needs Maximizing Potential of Next-generation Immunomodulator B
Slide 5: BNT327: Potential to Establish a New Standard of Care Across Multiple Tumor Types
BNT327: Potential to Establish a New Standard of Care Across Multiple Tumor Types 5 Clinical activity across indications Including SCLC, NSCLC, TNBC, RCC, MPM and others Including studies in 1L or 2L+ with SoC & novel combinations Focus on 1L TNBC, SCLC, and NSCLC 1. Indications included: HCC, ovari
Slide 6: Harnessing Complementary Expertise to Maximize BNT327 Potential
Harnessing Complementary Expertise to Maximize BNT327 Potential 6 Leadership position in the PD-(L)1xVEGF space and personalized mRNA cancer immunotherapies Pioneer in shaping IO field, focused on further bolstering leadership position in oncology Patient-centric scientific excellence Unique pipelin
Slide 7: Deal Terms
Deal Terms1 1. All deal terms subject to the subsequent Amended and Restated Agreement. 7 Financial Milestones Profit & loss sharing Co- Commercialization Co-Development Cost share of joint trials 50:50 (subject to certain exceptions) BioNTech and BMS retain full rights to exploit any of its proprie
Slide 8: Abbreviation Directory
Abbreviation Directory n L nth line VEGF-A Vascular endothelial growth factor A ADC Antibody-drug conjugate VHH Heavy chain variable BMS Bristol Myers Squibb SoC Standard of care BNT BioNTech TNBC Triple-negative breast cancer BTC Biliary tract cancer UK United Kingdom CTx Chemotherapy US United Sta